Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Zacks11-07

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481160643?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","is_english":true,"pubTime":"2024-11-07 23:58","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481160643","market":"us","top_or_hot":-1,"title":"Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y","media":"Zacks","content":"<div>\n<p>Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred ...</p>\n\n<a href=\"https://finance.yahoo.com/news/esperions-q3-loss-wider-expected-155800023.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 23:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/esperions-q3-loss-wider-expected-155800023.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred ...</p>\n\n<a href=\"https://finance.yahoo.com/news/esperions-q3-loss-wider-expected-155800023.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESPR","symbol_name":"Esperion Therapeutics Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/esperions-q3-loss-wider-expected-155800023.html","article_id":"2481160643","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481160643","pubTimestamp":1730995080,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.Esperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of $55 million.Shares of Esperion were down in pre-market trading on Nov. 7 owing to the weaker-than-expected results.Stay up-to-date with all quarterly releases:See ZacksEarnings Calendar.Esperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet — that are approved for treating elevated LDL-C  and cardiovascular risk reduction. These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets  in partnership with Daiichi Sankyo. The company records royalties on sales of its dr","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ESPR":"Esperion Therapeutics Inc."},"translate_title":"Esperion第三季度亏损超出预期，收入同比增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":0.9},"content_text":"Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.\nEsperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of $55 million.\nShares of Esperion were down in pre-market trading on Nov. 7 owing to the weaker-than-expected results.\nStay up-to-date with all quarterly releases: See Zacks Earnings Calendar.\nMore on ESPR's Q3 Results\nEsperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet — that are approved for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. These two oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.\nProduct revenues, solely from the United States, totaled $31.1 million in the third quarter, up almost 53% year over year. The upside was driven by continued prescription growth. During the quarter, the drugs’ total retail prescription increased 44% year over year and 12% sequentially.\nProduct revenues beat the Zacks Consensus Estimate of $29.9 million.\nEsperion recorded collaboration revenues, including combined royalty and partner revenues, of $20.5 million during the third quarter, up almost 50% year over year. The upside was driven by increases in royalty sales as well as higher revenues recognized from the litigation-related settlement received from Daiichi Sankyo Europe (DSE),\nCollaboration revenues missed the Zacks Consensus Estimate and our model estimate of $25.5 million and $33.2 million, respectively.\nShares of Esperion have plunged 26.1% so far this year compared with the industry’s decline of 3.4%.\nImage Source: Zacks Investment Research\nResearch and development expenses declined 30% from the year-ago period’s levels to $10.4 million, primarily related to the close-out of the company’s CLEAR Outcomes study.\nSelling, general and administrative expenses were up 20% year over year to $40 million. The rise was due to an increase in the company’s sales force, in addition to bonus payments and promotional costs.\nAs of Sept 30, 2024, Esperion had cash, cash equivalents, restricted cash and investment securities of $144.7 million compared with $189.3 million as of June 30, 2024.\n2024 Guidance\nEsperion reiterated its financial outlook for 2024. The company continues to expect operating expenses in the range of $225-$245 million, including $20 million in non-cash expenses related to stock compensation.\nESPR's Recent Updates\nThe European Commission approved a label update for Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events in May 2024. Nustendi is a fixed-dose combination of bempedoic acid and ezetimibe.\nHypercholesterolemia indicates elevated levels of cholesterol in the blood.\nFollowing the label expansion in Europe, Nilemdo and Nustendi became the first and only treatments for lowering LDL-C, approved for primary and secondary prevention of CV events.\nAdditionally, the updated labels support the use of Nilemdo and Nustendi either alone or in combination with statins.\nPer the company, in the third quarter of 2024, there were more than 23,500 healthcare practitioners writing scripts for Nexletol and Nexlizet.\n\nEsperion Therapeutics, Inc. Price, Consensus and EPS Surprise\n  \nEsperion Therapeutics, Inc. price-consensus-eps-surprise-chart | Esperion Therapeutics, Inc. Quote\n\nESPR's Zacks Rank & Key Picks\nEsperion currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the biotech sector are CRISPR Therapeutics AG CRSP, Lisata Therapeutics, Inc. LSTA and Amicus Therapeutics, Inc. FOLD, each carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. Loss per share estimates for 2025 have narrowed from $4.98 to $4.94 during the same time. Year to date, shares of CRSP have decreased 19%.\nCRSP’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 100.64%.\nIn the past 60 days, estimates for Lisata Therapeutics’ 2024 loss per share have narrowed from $2.97 to $2.90. Loss per share estimates for 2025 have narrowed from $2.61 to $2.53 during the same time. Year to date, shares of LSTA have increased 6.9%.\nLSTA’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.75%.\nIn the past 60 days, estimates for Amicus’ 2024 earnings per share have moved up from 21 cents to 22 cents. Earnings per share estimates for 2025 have improved from 50 cents to 53 cents during the same time. Year to date, shares of FOLD have declined 20.8%.\nFOLD’s earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 23.96%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAmicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report\nEsperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report\nCRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report\nLisata Therapeutics, Inc. (LSTA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481160643"}